ReviewJournal of hepatocellular carcinoma2025
Natural Bioactive Compounds Targeting the Wnt/β-Catenin Pathway for the Treatment of Hepatocellular Carcinoma.
Review in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Post-marketing safety assessment of tetrandrine based on the WHO-VigiAccess database.Medicine · 2026Article
- Food-Derived Natural Compounds as Molecular Targets in Cancer Prevention.Pharmaceutics · 2026Review
- Caffeine in the Context of Sorafenib Chemotherapy: Insights From Experimental Hepatocarcinogenesis.Journal of biochemical and molecular toxicology · 2026Article
- Targeting the WNT/β-Catenin Pathway in Hematological Malignancies: From Molecular Pathogenesis to Emerging Therapeutic Strategies.Biomolecules · 2026Review
- Mechanistic study of the role of emodin in targeting and inhibiting the Rap1 signaling pathway to regulate epithelial-mesenchymal transition and reverse cisplatin resistance in hepatocellular carcinoma.Translational cancer research · 2026Article
- Targeting CXCR6 Disrupts β-Catenin Signaling and Enhances Sorafenib Response in Hepatocellular Carcinoma.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with limited treatment options and poor prognosis. The Wnt/β-catenin signaling pathway is a key regulator of cellular proliferation, differentiation, and stem cell maintenance, and is frequently dysregulated in HCC, contributing to tumor progression, metastasis, and drug resistance. Natural bioactive compounds (NBCs) have emerged as promising treatments due to their multi-targeted mechanisms, low toxicity, and ability to modulate key oncogenic pathways. This review examines the potential of NBCs to target the Wnt/β-catenin pathway in HCC. Compounds such as curcumin, emodin, gallic acid, and ginsenosides exhibit anti-tumor effects by inhibiting β-catenin nuclear translocation, inducing autophagy, suppressing angiogenesis, and modulating the tumor microenvironment. For example, curcumin inhibits HCC cell proliferation and invasion by downregulating lncRNA expression and EMT markers, thereby inactivating the Wnt/β-catenin signaling pathway. Additionally, alkaloids like tetrandrine and toosendanin reduce metastasis through pathway-specific inhibition and epigenetic modulation. These compounds demonstrate potential as standalone therapies, and also in combination with conventional treatments like sorafenib by enhancing the effectiveness and overcoming resistance. However, challenges such as limited bioavailability, stability, and the intricate interplay of the Wnt/β-catenin pathway with other signaling pathways highlights the need for advanced delivery systems and combination strategies. In conclusion, future research should prioritize clinical validation, precision medicine approaches, and exploration of the role of NBCs in cancer stem cell regulation. Collectively, NBCs targeting the Wnt/β-catenin pathway offer a novel, safer, and multi-faceted approach for improving HCC treatment outcomes, paving the way for their integration into standard therapeutic regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.